Compare Vanguard Ultra Short Bond ETF (VUSB) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Ultra Short Bond ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Ultra Short Bond ETF trades at $49.7, while State Street SPDR S&P Biotech ETF trades at $159.82. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Vanguard Ultra Short Bond ETF nearer its low. Which is the better fit depends on your goals.
| VUSB | XBI | |
|---|---|---|
Sector | Leveraged / Inverse | Broad Market / Factor |
52-Week High | $50.03 | $164.28 |
52-Week Low | $49.60 | $86.92 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VUSB trades at $49.695, up 0.07% on the day, with a bearish technical outlook indicated by moving averages and ADX signals. Recent news highlights short-term bond ETF appeal amid potential Fed rate hikes. Financial ratios are unavailable, but the fund maintains consistent dividend distributions, with recent payouts around $0.17-$0.18 per share.
The outlook is cautious due to bearish technicals and interest rate sensitivity. Opportunities lie in short-term bond stability if rates rise, but risks include Fed policy shifts and market volatility. Investors should weigh dividend consistency against broader fixed-income pressures.
XBI trades at $159.15, up 0.71% with a bullish technical signal from moving averages. The biotech ETF shows strong momentum with a 17% monthly gain, driven by positive clinical data and M&A activity. Analyst coverage remains limited with a single hold rating, while institutional interest grows with recent $793,000 investment from Bay Colony Advisors.
Outlook remains positive given biotech sector resurgence, though elevated RSI suggests near-term overbought conditions. Key risks include sector volatility and regulatory uncertainty, but AI-driven drug discovery and strong pipeline developments provide growth catalysts for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
